CD22 and nervous system disorder: Similarly, the CD22 downregulation observed in patients receiving CD22-directed CAR T-cell therapy demonstrates another escape mechanism that may contribute to neurological disease progression and associated symptoms, as CD22-negative cells can continue to proliferate within the CNS despite the presence of CAR T cells [68].